Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ICARES MedicusROCO:6612 -0.14%86 Return-on-Tangible-Asset is 6.51% as of Mar. 2026, which is 16% below its 10-year median of 7.73. GuruFocus rates ROCO:6612 with a GF Score™ of 86/100 and a GF Value™ of NT$172.67 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 853 Medical Devices & Instruments companies, ICARES Medicus ranks better than 53.22% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. ICARES Medicus's annualizedNet Income for the quarter that ended in Mar. 2026 was NT$153 Mil. ICARES Medicus's average total tangible assets for the quarter that ended in Mar. 2026 was NT$2,354 Mil. Therefore, ICARES Medicus's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 6.51%.
The historical rank and industry rank for ICARES Medicus's Return-on-Tangible-Asset or its related term are showing as below:
ROCO:6612'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 1.85 Med: 7.73 Max: 14.87
Current: 1.85
During the past 13 years, ICARES Medicus's highest Return-on-Tangible-Asset was 14.87%. The lowest was 1.85%. And the median was 7.73%.
ROCO:6612's Return-on-Tangible-Asset is ranked better than 53.22% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 0.76
vs ROCO:6612: 1.85
ICARES Medicus (ROCO:6612) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
ICARES Medicus Return-on-Tangible-Asset Related Terms
ICARES Medicus Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for ICARES Medicus's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6612 vs ISRG, BDX, MDLN: Return-on-Tangible-Asset Comparison
For the Medical Instruments & Supplies subindustry, ICARES Medicus's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ICARES Medicus Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ICARES Medicus's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where ICARES Medicus's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 6.51% mean?
ICARES Medicus (ROCO:6612) has a Return-on-Tangible-Asset of 6.51% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on ICARES Medicus and its competitors. This is 16% below median its historical median of 7.73. Over the past decade, ICARES Medicus' Return-on-Tangible-Asset has ranged from 1.85 to 14.87. According to the industry distribution chart, ICARES Medicus ranks #399 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 46.8%.
Is ICARES Medicus' Return-on-Tangible-Asset too high?
ICARES Medicus' current Return-on-Tangible-Asset of 6.51% is 16% below median its 10-year median of 7.73. Over the past 10 years, this metric has ranged from a low of 1.85 to a high of 14.87. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.76. ICARES Medicus' value of 6.51% is 756.6% above this industry median. Based on the distribution chart, ICARES Medicus ranks #399 out of 853 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, ICARES Medicus has a GF Score™ of 86/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ICARES Medicus' Return-on-Tangible-Asset compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, ICARES Medicus ranks #399 out of 853 companies for Return-on-Tangible-Asset. This puts ICARES Medicus in the upper half of its industry. The industry median Return-on-Tangible-Asset is 0.76. ICARES Medicus' value of 6.51% is 756.6% above this benchmark. Historically, ICARES Medicus' own Return-on-Tangible-Asset has ranged from 1.85 to 14.87 over the past decade. While the company's 10-year median is 7.73 vs. the industry median of 0.76, ICARES Medicus has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.76, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ICARES Medicus's current Return-on-Tangible-Asset of 6.51% is 756.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on ICARES Medicus and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ICARES Medicus's current Return-on-Tangible-Asset is 6.51%, which is 16% below median its own 10-year median of 7.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ICARES Medicus stock overvalued right now?
Based on GuruFocus' analysis, ICARES Medicus (ROCO:6612) is currently considered Possible Value Trap. The stock's GF Value™ is NT$172.67, compared to a current price of NT$73.30 — trading 57.5% below its estimated fair value. The current Return-on-Tangible-Asset is 6.51%, which is 16% below median its 10-year median of 7.73 and 756.6% above the Medical Devices & Instruments industry median of 0.76. ICARES Medicus' overall GF Score™ is 86/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For ICARES Medicus (ROCO:6612), the current Return-on-Tangible-Asset is 6.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ICARES Medicus (ROCO:6612) Overvalued in 2026?
Based on GuruFocus' analysis, ICARES Medicus stock appears to be undervalued.
The current stock price of NT$73.30 is trading 57.5% below its estimated GF Value™ of NT$172.67.
GuruFocus considers ICARES Medicus to be Possible Value Trap.
Key valuation signals for ROCO:6612:
Return-on-Tangible-Asset: 6.51% (16% below median its 10-year median of 7.73)
GF Value™: NT$172.67 vs. price of NT$73.30 (57.5% below fair value)
Industry Position: 756.6% above the Medical Devices & Instruments median (#399 of 853)
No single metric tells the full story. See the ROCO:6612 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ICARES Medicus Inc is engaged in providing high-grade nanomedical lubricious coatings and various surface treatments for implantable or interventional medical devices. In addition, it also designs, develops, manufactures, and sells intraocular lenses and nanomedical devices. The company's operating segments are Europe and America, which derive maximum revenue, China, and R.O.C. Geographically, it generates maximum revenue from the United States, followed by Taiwan, Spain, England, Japan, China, Germany, and other countries.
86GF Score
Get the complete analysis for ROCO:6612
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6612 has been successfully added to your 
